VEGF Rat
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
The VEGF is purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Vascular Endothelial Growth Factor (VEGF) is a signal protein that stimulates the formation of blood vessels. It is a crucial factor in both physiological and pathological angiogenesis. VEGF is known for its role in promoting the growth of new blood vessels during embryonic development, after injury, and in response to muscle exercise. It also plays a significant role in the formation of new blood vessels in tumors, which is essential for their growth and metastasis.
VEGF is a glycosylated mitogen that specifically acts on endothelial cells. It has several isoforms, with VEGF-A being the most studied. VEGF-A is involved in mediating increased vascular permeability, inducing angiogenesis and vasculogenesis, promoting endothelial cell growth, and inhibiting apoptosis. The protein binds to tyrosine kinase receptors on the surface of endothelial cells, primarily VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), which triggers a cascade of downstream signaling pathways that promote cell proliferation, migration, and survival .
Recombinant VEGF, including rat recombinant VEGF, is produced using recombinant DNA technology. This involves inserting the gene encoding VEGF into a suitable expression system, such as bacteria, yeast, or mammalian cells, which then produce the protein. Recombinant VEGF is used in various research and therapeutic applications, including studies on angiogenesis, cancer, and cardiovascular diseases .
VEGF is a key regulator of angiogenesis, the process by which new blood vessels form from pre-existing vessels. This process is vital for normal development and wound healing. In pathological conditions, such as cancer, excessive angiogenesis can occur, leading to tumor growth and metastasis. VEGF promotes angiogenesis by binding to its receptors on endothelial cells, stimulating their proliferation and migration, and increasing vascular permeability .
Due to its critical role in angiogenesis, VEGF has been a target for therapeutic interventions. Anti-VEGF therapies, such as monoclonal antibodies and small molecule inhibitors, have been developed to treat various cancers by inhibiting tumor angiogenesis. Additionally, VEGF-based therapies are being explored for their potential to promote blood vessel growth in ischemic tissues, such as in heart disease and peripheral artery disease .
